PepGen (PEPG) Competitors $1.48 -0.13 (-8.07%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.54 +0.06 (+4.39%) As of 03/28/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. INMB, TVGN, VYGR, ELDN, INBX, ACIU, DMAC, BTMD, SOPH, and NGNEShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include INmune Bio (INMB), Tevogen Bio (TVGN), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), AC Immune (ACIU), DiaMedica Therapeutics (DMAC), biote (BTMD), SOPHiA GENETICS (SOPH), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. PepGen vs. INmune Bio Tevogen Bio Voyager Therapeutics Eledon Pharmaceuticals Inhibrx AC Immune DiaMedica Therapeutics biote SOPHiA GENETICS Neurogene PepGen (NASDAQ:PEPG) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Which has more volatility & risk, PEPG or INMB? PepGen has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Does the MarketBeat Community believe in PEPG or INMB? INmune Bio received 124 more outperform votes than PepGen when rated by MarketBeat users. However, 80.00% of users gave PepGen an outperform vote while only 76.60% of users gave INmune Bio an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes2080.00% Underperform Votes520.00% INmune BioOutperform Votes14476.60% Underperform Votes4423.40% Is PEPG or INMB more profitable? PepGen's return on equity of -60.17% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% INmune Bio N/A -117.48%-78.96% Do institutionals and insiders hold more shares of PEPG or INMB? 58.0% of PepGen shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 4.6% of PepGen shares are held by company insiders. Comparatively, 35.2% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor PEPG or INMB? In the previous week, INmune Bio had 3 more articles in the media than PepGen. MarketBeat recorded 5 mentions for INmune Bio and 2 mentions for PepGen. INmune Bio's average media sentiment score of 1.26 beat PepGen's score of 0.31 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PEPG or INMB? PepGen currently has a consensus price target of $10.33, indicating a potential upside of 598.20%. INmune Bio has a consensus price target of $22.80, indicating a potential upside of 203.19%. Given PepGen's higher possible upside, equities analysts clearly believe PepGen is more favorable than INmune Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better valuation & earnings, PEPG or INMB? INmune Bio has higher revenue and earnings than PepGen. INmune Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.84-0.52INmune Bio$42K4,761.06-$30.01M-$2.18-3.45 SummaryINmune Bio beats PepGen on 11 of the 17 factors compared between the two stocks. Remove Ads Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.38M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-0.507.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.336.396.894.23Net Income-$78.63M$142.12M$3.20B$247.15M7 Day Performance-16.38%-5.18%-3.02%-2.17%1 Month Performance-53.02%-7.49%1.63%-5.68%1 Year Performance-89.93%-8.78%9.74%-0.67% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.3428 of 5 stars$1.48-8.1%$10.33+598.2%-89.9%$48.38MN/A-0.5030INMBINmune Bio1.9546 of 5 stars$8.30+2.2%$22.80+174.7%-36.0%$220.71M$42,000.00-3.8110Earnings ReportNews CoverageTVGNTevogen Bio3.1772 of 5 stars$1.24+8.8%$7.10+472.6%-68.0%$217.06MN/A0.003VYGRVoyager Therapeutics4.6208 of 5 stars$3.91+0.8%$14.86+280.0%-60.8%$215.86M$80.00M5.51100ELDNEledon Pharmaceuticals1.7738 of 5 stars$3.61+2.8%$12.50+246.3%+62.6%$215.66MN/A-1.8010Analyst RevisionNews CoveragePositive NewsINBXInhibrx1.8699 of 5 stars$14.72+2.6%N/A-59.6%$213.09M$200,000.000.00166Short Interest ↓ACIUAC Immune2.4687 of 5 stars$2.12+1.0%$12.00+466.0%-33.1%$212.87M$27.31M-4.61140Short Interest ↑Positive NewsDMACDiaMedica Therapeutics1.8545 of 5 stars$4.95-0.6%$8.00+61.6%+37.9%$212.14MN/A-8.8420BTMDbiote3.5814 of 5 stars$3.90+1.0%$8.00+105.1%-41.6%$211.91M$197.19M15.00194Positive NewsGap UpSOPHSOPHiA GENETICS2.6893 of 5 stars$3.12+3.3%$6.80+117.9%-33.9%$208.06M$65.17M-2.86520Short Interest ↓Gap UpNGNENeurogene1.9771 of 5 stars$13.96-1.8%$60.80+335.5%-71.5%$207.38M$925,000.000.0090Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies INmune Bio Alternatives Tevogen Bio Alternatives Voyager Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Inhibrx Alternatives AC Immune Alternatives DiaMedica Therapeutics Alternatives biote Alternatives SOPHiA GENETICS Alternatives Neurogene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PEPG Stock Free PEPG Stock Alerts